Currently, the UK accounts for 16% of global cell therapy manufacturing facilities, according...
REBLOZYL® (luspatercept-aamt) for the Treatment of Anaemia Associated with Beta-Thalassemia
REBLOZYL® (luspatercept-aamt) is a novel erythroid maturation agent (EMA) approved to treat anaemia associated with beta-thalassemia in adult patients who require regular red blood cell (RBC) transfusions.
Manufacturers Choose the Mastersizer 3000 for Accuracy and Efficiency
In 2016, Metals and Additives LLC, a leading manufacturer and supplier of powder additives for the battery and plastics industries, purchased the Mastersizer 3000 from Malvern Panalytical.
August’s top news stories
Biopharmaceutical firm Retrophin reported that the Phase III clinical trial of fosmetpantotenate failed to meet endpoints in pantothenate kinase-associated neurodegeneration (PKAN) patients; and MyoKardia has commenced dosing of patients in a Phase I trial of small molecule MYK-224 for the treatment of hypertrophic cardiomyopathy (HCM). Clinicaltrialsarena.com wraps up the key headlines from August 2019.
PCI Pharma to invest in new clinical facility in Dublin
PCI Pharma is set to invest in a new clinical facility near Dublin, Ireland to significantly increase capabilities and capacity for its clinical services business.
May’s top news stories
Novartis reported that the first clinical trial in its Phase III PLATINUM programme for QMF149 has met primary and key secondary endpoints in people with inadequately controlled asthma; and The National Institute of Allergy and Infectious Diseases (NIAID) has reported findings from a Phase I/II clinical trial of Okairos’ AdCh3NSmut1/MVA-NSmut vaccine. Drugdevelopment-technology.com wraps up the key headlines from May 2019.
April’s top news stories
Chinese clinical-stage biopharmaceutical company I-Mab Biopharma and German biotech company MorphoSys have begun the first dosed Phase III clinical study to assess investigational human CD38 antibody TJ202/MOR202 in combination with lenalidomide in patients suffering from relapsed or refractory multiple myeloma; and A small clinical trial by researchers at the University of Edinburgh in the UK has showed that cilostazol and isosorbide mononitrate could prevent recurrence of stroke and vascular dementia. Drugdevelopment-technology.com wraps up the key headlines from April 2019.
Governments are playing a bigger role in cell and gene therapy manufacturing
Currently, the UK accounts for 16% of global cell therapy manufacturing facilities, according to GlobalData’s Contract Service Provider Database.
Timothy McGrath Appointed Chief Operating Officer of Newly Merged NEOMED-LABS / Pacific Biomarkers
The newly merged NEOMED-LABS / Pacific Biomarkers, an immunology centric service provider specialized in assay development and clinical laboratory testing for vaccines and soluble large molecules, announced today the appointment of Tim McGrath to the role of Chief Operating Officer.
January’s top news stories
Janssen Pharmaceutical Companies of Johnson & Johnson unblinded the Phase III TITAN trial investigating Erleada (apalutamide) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).